Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAIR-ALS II: Deferiprone in Amyotrophic Lateral Sclerosis
NCT03293069Phase 3Completed
- Sponsor
- CHU de Lille
- Start
- Jan 2019
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of deferiprone in amyotrophic lateral sclerosis (ALS), sponsored by CHU de Lille. Started Jan 2019; status: completed.
02
Drugs
deferiprone
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03293069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03293069.